UARK 2003-26, a pilot study of MAGE-A3 and NY-ESO-1 immunotherapy in combination with DTPACE chemotherapy and autologous transplantation in multiple myeloma.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cancer vaccine NY-ESO-1 (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Thalidomide; Zastumotide
Indications Multiple myeloma
Focus Therapeutic Use

24 Jun 2013 Biomarkers information updated
19 Dec 2012 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.
22 Oct 2005 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com